Abstract: Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that specifically target human cyclophilin A (CyPA) to effectively inhibit Hepatitis C (HCV) infection in a cell. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or as pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with known delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc., HCV infection using such siRNA and shRNAs and compositions comprising same are also provided.

Abstract: The invention provides compounds represented by the formulae: (I) and (II) where the compounds are useful in treating, for example, viral and/or parasitic infections. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds.

Abstract: Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for pulmonary fibrosis, which utilized the carrier; and a preparation kit of the therapeutic agent.

Abstract: Compounds having unique properties are prepared from the herbal compositions described herein and comprise extracts derived from plants and fungi of the genera Panax, Ganoderma, and Saussurea. The compositions are useful in preventing, treating, relieving, and improving the quality-of-life of patients suffering from chronic diseases, such as liver diseases, cancer, cachexia, and immune system disorders.

Abstract: The present invention provides stable encapsulated (?)-hydroxycitric acid (“HCA”)-containing compositions and methods of making the same. A method is provided by which the hygroscopic salts of HCA in their relatively pure and active forms, including especially the potassium salt, but also including the sodium salt, are rendered non-hygroscopic and stable (that is, not prone to lactonization, not readily subject to attachment to ligands which inhibit absorption or lead to excretion, and so forth) such that these HCA salts might be included in dry delivery formats, liquid delivery and in controlled-release vehicles. The nonhygroscopic salts of HCA and its derivatives likewise may be protected against acid degradation, lactonization and undesirable ligand binding when exposed to acidic environments or other challenging conditions. The method taught herein can be employed to reduce the polar/ionic qualities of HCA salts and derivatives when presented to the intestinal lumen to provide advantages in absorption.

Abstract: The invention relates to a tamper-resistant tablet comprising (i) a matrix material in an amount of more than one third of the total weight of the tablet; and (ii) a plurality of coated particulates in an amount of less than two thirds of the total weight of the tablet; wherein said particulates comprise a pharmacologically active compound and a physiologically acceptable polymer, preferably a polyalkylene oxide; and form a discontinuous phase within the matrix material; which preferably provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.; and method of using said tablet to treat pain and other conditions.

Abstract: The invention relates generally to pharmaceutical compositions comprising rifaximin effective at treating vaginal infections, and in particular bacterial vaginosis. The pharmaceutical compositions comprising rifaximin granules are characterized in that they release rifaximin in the vagina in a controlled way. The present invention also relates to processes for preparation of the rifaximin pharmaceutical compositions and their use in the treatment of vaginal infections. Effective dosages and courses of treatment useful and effective at recovering from the disease and preventing any possible relapse are also provided.

Abstract: The invention relates to a tamper-resistant tablet comprising (i) a matrix material in an amount of more than one third of the total weight of the tablet; and (ii) a plurality of particulates in an amount of less than two thirds of the total weight of the tablet; wherein said particulates comprise a pharmacologically active compound and a polyalkylene oxide; and form a discontinuous phase within the matrix material; and method of using said tablet to treat pain and other conditions.

Abstract: The present invention relates to a particulate material and a solid dosage form notably tablets comprising a regularly shaped calcium-containing compound such as a calcium salt as a therapeutically and/or prophylactically active substance and a pharmaceutically acceptable sugar alcohol such as, e.g., sorbitol and/or isomalt that has a micro structure as evidenced by SEM. The invention also relates to a process for the preparation of the particulate material and solid dosage form. The process involves agglomeration of the calcium-containing compound and the pharmaceutically acceptable sugar alcohol by means of roller compaction. The particulate material obtained by roller compaction is suitable for use in the further processing of the particulate material into e.g. tablets such as chewing tablets.

Abstract: Provided is a pharmaceutical formulation in the form of a bilayered tablet consisting of a first layer containing irbesartan or a pharmaceutically acceptable salt thereof and a second layer containing an HMG-CoA reductase inhibitor and a basic additive, which can improve the dissolution rate and stability of irbesartan and an HMG-CoA reductase inhibitor to enhance the bioavailability of the drug compared to conventional complex formulations and to minimize the generation of the related compounds, thereby being effectively used as a stable and superior therapeutic agent for hypertension and hypercholesterolemia.

Abstract: The present invention provides a hemostatic porous composite sponge comprising i) a matrix of a biomaterial and ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that—said polymeric component is coated onto a surface of said matrix of a biomaterial, or—said matrix is impregnated with said polymeric material, or—both.

Abstract: A process for preparing a spray-dried product for improving the rate of dissolution of the active ingredient. The process includes mixing a crystalline active ingredient, which has a dissolution rate in unstirred water at 25° C. of greater than 15 minutes at a concentration of 14 ppm of the active ingredient, with a starch derivative, a second carrier material, and optionally, xanthan gum, to form a suspension, dispersion or solution of the active ingredient; homogenizing the mixture at a pressure of at least 4000 psig (2.758×107 Pa); and spray-drying the homogenized mixture to provide a spray-dried active ingredient that has an increased dissolution rate in water compared to the unencapsulated active ingredient.

Abstract: The present invention relates to a pharmaceutical powder composition for inhalation comprising an active ingredient and a pharmaceutically acceptable carrier, process for preparing such composition, and its use for the treatment of respiratory disorder in a subject.

Abstract: Provided herein are compositions, methods, systems, and kits for wound healing. As shown herein, CCN2/CTGF stimulated mesenchymal progenitor cells can form ?SMA? fibroblasts. Further, TGF? was shown to stimulate further differentiation of ?SMA? fibroblasts to myofibroblasts associated with fibrosis. One aspect provides a composition including CCN2/CTGF and a TGF? inhibitor, a P38 inhibitor, or a tyrosine kinase inhibitor. Another aspect provides a method of treating tissue wounds with CCN2/CTGF-containing compositions. Also provided are systems and kits for wound healing. Also provided are methods for forming ?SMA? fibroblasts mesenchymal progenitor cells.

Abstract: A topical composition and method for making, including the steps of placing cow's tallow in water and heating; allowing the heating tallow to float to the top of the water; filtering the floating portion of the tallow from the rest of the water; placing the floating portion of tallow obtained from the filtering into a container containing the bee's wax, camphor, and alum powder; maintaining the mixture at low heat; allowing all four ingredients to have blended; cooling the mixture from the low heat; and refrigerating the mixture. The temperature of heating the cow's tallow is sufficient to render the four ingredients blendable.

Abstract: The present invention relates to compositions comprising complexes of human cells and polymer fibers and methods of their use for therapeutic purposes. Methods of making such compositions are also provided. The present invention encompasses compositions comprising poly-?-1?4-N-acetylglucosamine polymers and stored platelets and their use for promoting wound healing and achieving hemostasis.

Abstract: A method for producing sterile, decellurized bioprosthetic tissue comprising: (a) contacting a human tissue with a hypotonic solution to produce a lysed tissue, (b) contacting the lysed tissue with a first surfactant to produce a surfactant-treated tissue, (c) contacting the surfactant-treated tissue with a nuclease enzyme solution to produce an enzyme-treated tissue, (d) contacting the enzyme-treated tissue with a cleaning solution comprising a second surfactant, a chaotropic agent or a mixture thereof to produce a decellurized tissue and (e) contacting the decellurized tissue with a bioburden reducing agent to produce the final bioprosthetic tissue. Kits to be used in conjunction with said method, as well as, the bioprosthetic tissue produced via said method are also provided.

Abstract: The purpose of the present invention is to provide a medicinal agent which is useful for amelioration or treatment of chronic prostatitis, interstitial cystitis and/or urination disorders. The present invention relates to a novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and more particularly, it relates to an ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders containing the extract as an active ingredient. The medicinal agent of the present invention containing the extract as an active ingredient is extremely useful as a highly effective and highly safe ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders.

Abstract: There is provided on-demand, oxygen generating topical compositions having a built-in indicator specifically to indicate a color change upon the complete mixing of the oxygen precursor and catalyst. The first part of the composition contains a carrier and manganese dioxide (MnO2) nanoparticles. The second part of the composition comprises the oxygen precursor; hydrogen peroxide. When the two parts, one with manganese dioxide nanoparticles and exhibiting a characteristic color, (e.g. yellow brown) and the second part with hydrogen peroxide are mixed together, the color imparted by the manganese dioxide nanoparticles essentially disappears and the final composition (enriched with oxygen) either appears colorless or takes on the original color of the catalyst. Thus, the manganese dioxide catalyst nanoparticles themselves serve as the colorimetric indicator of peroxide decomposition to oxygen, precluding the need for an external colorant.

Abstract: Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers.

Abstract: Disclosed are compositions for treating or preventing migraine headaches and related headaches.

Abstract: A composition comprising a pharmaceutically acceptable group (2, 4, 12, 13 or 14) metal compound for the treatment of a dermatological condition involving an abnormal decrease in the cell-to-cell adhesion between epithelial cells in the epidermal barrier.

Abstract: A method treating psoriasis and more specifically toward a protocol that involves the use of a specialized curcumin gel composition, the use of topical steroid cream, the avoidance of contact with allergens, and lactose-free diet and treatment of bacterial superinfection with antibiotics and bleach/chlorox baths.

Abstract: This invention relates to a composition of a unique combination of three novel dietary supplements for use in a weight loss program. The composition includes a mood enhancer, an insulin sparing agent, and a peripheral energy blocker. Also provided is a method of treatment in a weight loss program.

Abstract: Targeting uncontrolled cell proliferation and resistance to DNA damaging chemotherapeutics with at least one reagent has significant potential in cancer treatment. Replication Protein A, the eukaryotic single-strand (ss) DNA binding protein, is essential for genomic maintenance and stability via roles in both DNA replication and repair. Reported herein are small molecules that inhibits the in vitro, in vivo, and cellular ssDNA binding activity of RPA, thereby disrupting the eukaryotic cell cycle, inducing cytotoxicity and increasing the efficacy of chemotherapeutic agents damage DNA, and/or disrupt its replication and/or function. These results provide new insights into the mechanism of RPA-ssDNA interactions in chromosome maintenance and stability. This represents a molecularly targeted eukaryotic DNA binding inhibitor and demonstrates the utility of targeting a protein-DNA interaction as a means of studying the cell cycle and providing a therapeutic strategy for cancer treatment.

Abstract: The present invention provides a method of using a solid-layered composition having at least two parts. The first past comprises a) calcium hypochlorite, magnesium hypochlorite and mixtures thereof, b) a builder, c) a water-soluble polymer, d) an acid, and e) wherein the first part does not contain sodium hypochlorite, lithium hypochlorite, potassium hypochlorite and mixtures thereof. The second part comprises a) a surfactant b) a builder, c) an acid, and d) wherein the second part does not contain any oxidant.

Abstract: This invention relates to a dietary supplement for use in a weight loss program, which alleviates insulin resistance in the presence of the metabolic syndrome. The dietary supplement includes, in combination, berberine, banaba leaf extract, and inositol. Also provided is a method of treatment in a weight loss program.

Abstract: An herbal-based solution includes a first amount of wasabi comprising at least an allyl isothiocyanate component, and a second amount of saline solution. The saline solution and the organic material are combined to substantially dilute the wasabi in the saline solution to produce the herbal-based solution. The herbal-based solution further has anti-inflammatory, anti-microbial and anti-coagulative properties. The wasabi may include Eutrema Wasabi. The herbal-based solution is deliverable as a nasal.

Abstract: This invention discloses composition and manufacturing processes of a toxicity free botanical drug formulation for curative treatment of chronic diseases. It is manufactured from plants Crinum asiaticum and Crocus sativus. This drug was administered to human volunteers by oral and intranasal routes in effective amount for an effective time period. Effective amount and effective time of administration varies from one human volunteer to another depending upon age, body weight, length of disease, severity of disease, type of the disease. In vitro experiments show that this botanical drug causes proliferation and differentiation of stem cells.

Abstract: A pomegranate pulp extract is disclosed. The pomegranate pulp extract is effective in relieving women's menopausal symptoms, anxiety disorders, depression or attention deficit disorders due to the presence of a large amount of ellagic acid. Further disclosed is a method for further improving the relieving effect of the pomegranate extract on women's menopausal symptoms, anxiety disorders, depression or attention deficit disorders. The method includes increasing the content of ellagic acid in the pomegranate extract.

Abstract: A synergistic composition comprising plant extracts rich in tannins for the treatment of topical viral infections. The plant extracts contain at least one protease inhibitor and/or at least one viral glycoprotein inhibitor.

Abstract: The present invention is directed to bioactive botanical cosmetic compositions derived from membrane and cell serum fractions of plant cell juice. The present invention also relates to the methods for preparing these bioactive botanical cosmetic compositions and the uses of these compositions in various cosmetic formulations and as topical skin cosmetic applications.

Abstract: The present invention relates to a composition containing extracts of Encelia canescens Lam and to aqueous or ethanolic extracts obtained therefrom, the procedure for the obtainment and crystallization thereof, and the uses thereof for the prevention and treatment of cancer, for example cancer of the pancreas, gastric tract, prostate, breast, kidney, colon, lung, vesicle, uterus, oral cavity, colorectal region, bladder, liver, brain tumors, and chronic and acute leukemia, in addition to metabolic diseases such as diabetes mellitus types I and II, viral and bacterial diseases, in particular related to E. coli, Kiebsiella, M flavus, S. aureus and B. subtilis. Furthermore the use thereof is claimed in diseases related to oxidative stress and as a useful agent in the preparation of analgesics.

Abstract: The molding die set includes: a first molding die having a first molding chase, a cavity piece, supported by the first molding chase, movably supported by the first molding chase and enclosing the cavity piece; a second molding die having a second molding chase, a work supporting section biased and supported by the second molding chase and on which a work will be mounted, and a center insert located adjacent to the work supporting section; and a pot being provided to one of the first molding die and the second molding die, the pot feeding resin for molding the work. The second molding die has a thickness adjusting mechanism, which makes the work supporting section absorb thickness variation of the work and brings the work into contact with the movable clamper when the work is clamped with the movable clamper of the first molding die.

Abstract: A device for continuous production of an extrudate from finely divided plant material and a thermoplastic material. When viewed in an extrusion direction, first the finely divided plant material and then the thermoplastic material are fed to an extrusion device, which can be a twin-screw extruder. The fed-in materials are mixed with one another, degassed and jointly extruded from the extrusion device and thus form the extrudate, and the plant material is embedded in the thermoplastic material, wherein the plant material and the thermoplastic material are fed into the extrusion device at a common position or two directly successive positions. The thermoplastic material is plastified in a separate plastifier extruder before being fed into the extrusion device and is fed from the extruder to the extrusion device in a plastified state, and the plant material is then degassed together with the thermoplastic material.

Abstract: A compression molding machine includes a feeder that has a feeder main body, a sealing frame attached to the feeder main body and having a supply port allowing a powdery material to pass therethrough, a first elastic member comprised between the sealing frame and the feeder main body, a sealing member attached to the sealing frame and preventing the powdery material from leaking, and a second elastic member comprised between the sealing member and the sealing frame.

Abstract: The present invention relates to a device for man facture of three-dimensional models by means of a 3D printing process, whereby a spreader device is used to deposit particulate material in layers on a build platform and the particulate material flow, which occurs perpendicular to the spreading direction, is transferred into containers that are actively cleaned by sliders or brushes at the spreader device. It exploits the fact that particulate material that is moves dynamically can only bridge small height differences. The arrangement can be implemented in a space-saving manner beneath the spreading plane.

Abstract: Embodiments of the invention are used to provide ways of tire tread molding and retreading with a double tread rubber body having a unitary structure that comprises two treads in order to remove the need for buffing an oxide layer typically associated with tread molding and curing. Embodiments of the double tread molding and retreading methods also remove the need for cementing the cured tread to prevent future oxidation buildup. Once the double tread is cured and cooled, it is cut along the centerline with a double tread separation apparatus to expose a soft non-oxidized inner rubber. The cutting is much less energy intensive when compared to buffing with an expendable wire brush. There is no risk of spots of oxidized rubber being missed as is the case with buffing. There is little or no dust created.

Abstract: A compression molding machine includes a plurality of plate units that are provided between a lower punch retainer and an upper punch retainer. The plate units each include: a plate having a through bore to be filled with a powdery material that is compressed by an upper punch and a lower punch; and a plate attachment member having a mount portion mounted to a vicinity of an upright shaft, a positioning surface positioning the upper surface of the plate, and a plate attaching portion attaching the plate from below to above, such that the upper surface of the plate is positioned at the positioning surface.

Abstract: Disclosed herein is, amongst other things, a molding apparatus, comprising a stripper sleeve (116) for use in a first stack portion (110) of a mold stack (140), wherein the stripper sleeve (116) is configured to open a slide pair (122) of the first stack portion (110) and to strip a molded article (106) from the first stack portion (110).

Abstract: The invention provides various bird feed mixtures that are intrinsically attractive to desirable birds such as finches. The bird feed mixture of the invention attracts larger numbers of desirable birds than commercially available bird feed mixtures. The bird feed mixtures contain thistle, red millet and sunflower chips.

Abstract: The invention provides a defined bird feed mixture that is intrinsically attractive to some desirable birds such as finches. The bird feed mixture of the invention attracts larger numbers of small birds than some commercially available finch bird feed mixtures. The bird feed mixture contains thistle, red millet and sunflower chips.

Abstract: The present invention relates to cocoa material, such as cocoa beans and products derived therefrom, such as chocolate. The invention in particular relates to flavour characteristics of such cocoa materials. In an aspect, the invention relates to cocoa beans or a derivative thereof of a first origin having at least one sensory characteristic which is substantially equal compared to the corresponding sensory characteristic of a bulk quantity of cocoa beans or a derivative thereof of a second origin, wherein said first and said second origin are different. The present invention also relates to methods suitable for obtaining such coca beans or derivatives therefrom.

Abstract: Provided are engineered meat products formed as a plurality of at least partially fused layers, wherein each layer comprises at least partially fused multicellular bodies comprising non-human myocytes and wherein the engineered meat is comestible. Also provided are multicellular bodies comprising a plurality of non-human myocytes that are adhered and/or cohered to one another; wherein the multicellular bodies are arranged adjacently on a nutrient-permeable support substrate and maintained in culture to allow the multicellular bodies to at least partially fuse to form a substantially planar layer for use in formation of engineered meat. Further described herein are methods of forming engineered meat utilizing said layers.

Abstract: Example embodiments provide an apparatus that is useful for recycling protein waste and producing fuel from protein waste. Waste is ground by a grinding means and digested by a enzyme digest medium composed of enzymes, preservatives, inedible egg and or a waste fluid that may include other protein sources with or without fat. The ground proteins are digested with the enzyme in recirculated digest tanks. Fat can be collected from the tank by addition of acid and separation of fat from water with a centrifuge. Alternatively the ground protein and enzyme can be fermented and gas collected from the digest tank in a pressure tank with a compressor. The protein solubles are emulsified, separated from water, and extruded before drying. Either fat or gas can be used to fuel a dryer. Example embodiments provide a highly digestable paletable food stuff from protein waste which is usable for pet, livestock, or an aquaculture diet.

Abstract: This invention relates to a process for manufacture of a dry enzyme containing mixer granulation granule comprising the step of adding a particulate component to the mixer granulation process, wherein the particulate component constitutes less than 75 parts of the finished granule and the particles of the particulate component have an mean size of more than 40 ?m in its longest dimension. Also claimed is granules of the process, granules containing more than two particles of the particulate component and composition and methods of using the granules.

Abstract: Provided are treats having an outer portion and an inner portion which contains a filing. The filling may include ground or diced meat and further includes additional ingredients for health benefits or palatability. The treats are highly palatable to pets and therefore very well-suited to delivery of health ingredients.

Abstract: Described herein is an edible coating for food products in which the coatings comprises a polysaccharide cross-linked with a cross-linking agent solution. Also described herein are methods for coating food products and forming clusters of food products. The use of the edible coating for extending the shelf-life of food products is also described.

Abstract: [Object] An object of the present invention is to provide a technique that allows commercialization of a carbonated beverage containing soybean powder and/or soymilk stored in a bottle in a condition that provides preservation stability for a long period of time. [Method for Achieving the Object] By storing a carbonated beverage containing soybean powder and/or soymilk in a bottle having a light transmittance of 10% or less for a wavelength of 250 to 650 nm, deterioration of the flavor of the carbonated beverage containing soybean powder and/or soymilk can be suppressed and long-term preservation stability can be maintained.

Abstract: A hollow body is made from a flat baked wafer cake by first juxtaposing the wafer cake with a cavity of a deep-drawing mold and then forming edge regions of the cake with a plurality of deformations out of a plane of the cake at a uniformly spacing around a periphery of the cake. Then the cake is pushed by a deep-drawing punch into the cavity to it into a hollow body and to form each of the deformations into a multilayer fold.